BACKGROUND: An analysis of 14 small cell lung cancer (SCLC) trials was performed to improve the current understanding of potential prognostic factors for overall survival (OS) and progression-free survival (PFS) in groups of patients with limited-stage disease SCLC (LD-SCLC) and extensive-stage disease SCLC (ED-SCLC) separately. METHODS: Data on 688 patients with LD-SCLC and 910 patients with ED-SCLC were included. Clinical and laboratory factors were tested for their prognostic significance using Cox regression models that were stratified by protocol. Recursive partitioning and amalgamation (RPA) analyses were used to identify prognostic subgroups. RESULTS: Poorer performance status (PS) led to worse OS and PFS in the ED-SCLC group but not in the LD-SCLC group. The prognostic impact of PS was strong for men but weak for women in the ED-SCLC group (interaction P value <.012 for OS and PFS). Other negative prognostic factors included increased age and men for the LD-SCLC group and increased age, men, increased number of metastatic sites at baseline, and increased creatinine levels for the ED-SCLC group. In patients with the ED-SCLC, RPA analyses identified 5 subgroups with different prognosis based on baseline PS, creatinine levels, sex, and the number of metastatic sites. CONCLUSIONS: The current pooled analysis identified baseline creatinine levels and the number of metastatic sites as important prognostic factors in patients with ED-SCLC in addition to the well established factors of sex, age, and PS. There was a significant interaction between sex and PS within the ED-SCLC group, suggesting that PS is highly prognostic in men but has no significant impact in women. Within the LD-SCLC group, only age and sex were identified as important prognostic factors. RPA analyses confirmed many of these findings. (c) 2009 American Cancer Society.
BACKGROUND: An analysis of 14 small cell lung cancer (SCLC) trials was performed to improve the current understanding of potential prognostic factors for overall survival (OS) and progression-free survival (PFS) in groups of patients with limited-stage disease SCLC (LD-SCLC) and extensive-stage disease SCLC (ED-SCLC) separately. METHODS: Data on 688 patients with LD-SCLC and 910 patients with ED-SCLC were included. Clinical and laboratory factors were tested for their prognostic significance using Cox regression models that were stratified by protocol. Recursive partitioning and amalgamation (RPA) analyses were used to identify prognostic subgroups. RESULTS: Poorer performance status (PS) led to worse OS and PFS in the ED-SCLC group but not in the LD-SCLC group. The prognostic impact of PS was strong for men but weak for women in the ED-SCLC group (interaction P value <.012 for OS and PFS). Other negative prognostic factors included increased age and men for the LD-SCLC group and increased age, men, increased number of metastatic sites at baseline, and increased creatinine levels for the ED-SCLC group. In patients with the ED-SCLC, RPA analyses identified 5 subgroups with different prognosis based on baseline PS, creatinine levels, sex, and the number of metastatic sites. CONCLUSIONS: The current pooled analysis identified baseline creatinine levels and the number of metastatic sites as important prognostic factors in patients with ED-SCLC in addition to the well established factors of sex, age, and PS. There was a significant interaction between sex and PS within the ED-SCLC group, suggesting that PS is highly prognostic in men but has no significant impact in women. Within the LD-SCLC group, only age and sex were identified as important prognostic factors. RPA analyses confirmed many of these findings. (c) 2009 American Cancer Society.
Authors: Julian R Molina; James R Jett; Nathan Foster; Bradley S Lair; Thomas J Carroll; Henry D Tazelaar; Shauna Hillman; James A Mailliard; Albert M Bernath; Daniel Nikcevich Journal: Am J Clin Oncol Date: 2006-06 Impact factor: 2.339
Authors: A T Turrisi; K Kim; R Blum; W T Sause; R B Livingston; R Komaki; H Wagner; S Aisner; D H Johnson Journal: N Engl J Med Date: 1999-01-28 Impact factor: 91.245
Authors: R J Kirschling; J P Grill; R S Marks; J W Kugler; J B Gerstner; S A Kuross; J C Michalak; H E Windschitl; K D Krewer; J R Jett Journal: Am J Clin Oncol Date: 1999-10 Impact factor: 2.339
Authors: Yolanda I Garces; Scott H Okuno; Steven E Schild; Sumithra J Mandrekar; Brian M Bot; John M Martens; Donald B Wender; Gamini S Soori; Dennis F Moore; Timothy F Kozelsky; James R Jett Journal: Int J Radiat Oncol Biol Phys Date: 2007-03-15 Impact factor: 7.038
Authors: R F Marschke; J P Grill; J A Sloan; D B Wender; R Levitt; J A Mailliard; J B Gerstner; C Ghosh; R F Morton; J R Jett Journal: Am J Clin Oncol Date: 1999-02 Impact factor: 2.339
Authors: Sumithra J Mandrekar; Steven E Schild; Shauna L Hillman; Katie L Allen; Randolph S Marks; James A Mailliard; James E Krook; Andrew W Maksymiuk; Kari Chansky; Karen Kelly; Alex A Adjei; James R Jett Journal: Cancer Date: 2006-08-15 Impact factor: 6.860
Authors: Jean-Paul Sculier; Kari Chansky; John J Crowley; Jan Van Meerbeeck; Peter Goldstraw Journal: J Thorac Oncol Date: 2008-05 Impact factor: 15.609
Authors: Steven E Schild; James A Bonner; Shauna Hillman; Timothy F Kozelsky; Antonio P G Vigliotti; Randolph S Marks; David L Graham; Gamini S Soori; John W Kugler; Richard C Tenglin; Donald B Wender; Alex Adjei Journal: J Clin Oncol Date: 2007-07-20 Impact factor: 44.544
Authors: A Zer; L Domachevsky; Y Rapson; M Nidam; D Flex; A M Allen; S M Stemmer; D Groshar; H Bernstine Journal: Eur Radiol Date: 2015-12-18 Impact factor: 5.315
Authors: Nathan R Foster; Yingwei Qi; Qian Shi; James E Krook; John W Kugler; James R Jett; Julian R Molina; Steven E Schild; Alex A Adjei; Sumithra J Mandrekar Journal: Cancer Date: 2010-10-19 Impact factor: 6.860
Authors: Ryoko Suzuki; Steven H Lin; Xiong Wei; Pamela K Allen; James W Welsh; Lauren A Byers; Ritsuko Komaki Journal: Radiother Oncol Date: 2018-02-02 Impact factor: 6.280